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LETTERS TO THE EDITOR
Alert to Physicians: Possible
Interaction of Aggrenox and Adenosine
A new medication, Aggrenox, a formulation of aspirin and
extended-release dipyridamole, is now being actively marketed to
physicians for the treatment of patients with transient ischemic
attacks and ischemic stroke. I believe that physicians involved in
pharmacological stress testing should recognize that patients tak-
ing this medicine may also be referred for an adenosine pharma-
cologic stress perfusion test. It would be anticipated that the
extended-release formulation of dipyridamole would antagonize
the breakdown of adenosine and, thereby, exaggerate adenosine’s
effects, including the induction of hypotension and atrial-
ventricular block. Patients receiving Aggrenox should not receive
adenosine but should receive dipyridamole instead. I believe the
readers of the Journal of the American College of Cardiology (JACC)
should be warned of the possible interaction of Aggrenox and
adenosine.
Steven R. Bergmann, MD, PhD
Department of Cardiology
Columbia University
College of Physicians & Surgeons
New York, New York 10032
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Pharmacists Agree:
Stop the Pharmacy Madness
I am writing in response to the editorial in the March issue of the
Journal of the American College of Cardiology (JACC) (1) concerning
the administrative challenges associated with insurance coverage
for prescription drugs which struck a resonant chord. As President
of the American Pharmaceutical Association (APhA), the national
professional society of pharmacists, I can assure you that my
profession is equally as frustrated with the inefficiencies and
unproductive hassles associated with many managed care programs
today. A recent study by Arthur Anderson shows that over 20% of
a pharmacist’s time is spent directly on activities related to
insurance issues (2). These include determining eligibility status,
resolving formulary and coverage issues and solving billing prob-
lems.
Because community pharmacies provide “point-of-service”
claims processing for prescription medications, pharmacists are
often placed in a difficult and undesirable position of mediating
insurance issues so that the patient can receive the prescribed
medication. Often, pharmacists must contact physicians for autho-
rization to change a patient’s medication to be compliant with the
plan formulary or to receive a prior authorization. These coverage
decisions are outside of the control of the pharmacist.
As you describe in your article, contacting the “help-desk” at an
insurance company is usually less-than-helpful. These call centers
are often understaffed with employees that are poorly trained and
unempowered to assist providers by authorizing clinical overrides.
This causes significant delays and often forces providers to make
decisions based on plan parameters as opposed to patient param-
eters.
I fully support the principles that you have outlined to “restore
rationality” to this process, but I suggest the addition of one
point—physicians and pharmacists must work together to ensure
changes in the design of health benefits that reduce the adminis-
trative burdens for all providers and, more importantly, facilitate
the efficient delivery of health care services to our patients.
As frustrating as these administrative barriers are to providers,
they are often even more frustrating and confusing for our patients.
Physicians and pharmacists must work toward building a medica-
tion delivery system where “care” is more important than “cover-
age.”
As you know, there are many other health care delivery issues we
could discuss but I am, as usual, tied up on the phone trying to
obtain authorization for Mrs. Brown’s heart medication which is,
not surprisingly, unavailable on her health care plan’s formulary.
Robert D. Gibson, PharmD
American Pharmaceutical Association
2215 Congress Avenue, Northwest
Washington, DC 20037
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The Pharmacy Perspective
on Managed Care Madness
I share your frustrations regarding the barriers to patient care as
described in your editorial entitled, “Pharmacy Madness” (JACC
2000;35:802–3). However, as a Doctor of Pharmacy (PharmD), I
find your description of the issue disturbing. The profession of
pharmacy is no more in control of the barriers you described than
the medical profession. Consistent with your description of your
P&T Committee experience, Managed Care permits medical
decisions (such as formulary inclusion or exclusion) to be made
based upon business cases and not patient risk versus benefit. This
is further perpetuated by patients’ willingness to enroll in (and thus
support) such healthcare organizations coupled with their lack of
willingness to pay for diagnostics or treatments not covered by
their plans.
Clinical pharmacists in the hospital setting are under many of
the same Managed Care pressures that physicians find themselves
under in that there is constant pressure to evaluate the costs most
closely tied to their function; while this correlates in part to
diagnostic procedures for physicians, it correlates to medications
for pharmacists. There is clearly a lack of understanding of the
clinical pharmacist’s expertise given that you view your institution’s
pharmacist as nothing more than a “SWAT team whose goal is to
reduce inpatient pharmaceutical costs in specific areas.”
Community pharmacists practicing in a retail setting are under
similar constraints. As pharmacists whose current primary role is to
dispense medication and advise regarding those medications, they
often find themselves as an involuntary liaison between the
insurance plans and the patients who chose to enroll in them.
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